In recent years therapeutic targeting of the estrogen receptor (ER: tamoxifen) and Her2 (trustazumab), in ER+ and Her2+ enriched subtypes have shown remarkable improvements with breast cancer therapy. This evidence concerns the gene ESR1 and breast cancer.